Skip to main content

Advertisement

SpringerLink
Log in

20-year risk of breast cancer recurrence

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF (2017) EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846. https://doi.org/10.1056/NEJMoa1701830

    Article  PubMed  Google Scholar 

  2. Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, Gelfand JM (2012) Medical record databases. In: Strom BL, Kimmel S, Hennessy S (eds) Pharmacoepidemiology, 5th edn. University of Pennsylvania, Philadelphia, pp 224–243

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Philipps-University Marburg, Marburg, Germany

    Karel Kostev & Matthias Kalder

  2. Epidemiology, IQVIA, Frankfurt, Germany

    Karel Kostev

Authors
  1. Karel Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Kalder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karel Kostev.

Ethics declarations

Conflict of interest

Karel Kostev and Matthias Kalder declares that they have no conflict of interest.

Disclosures

None.

Research involving human participants/informed consent

German law allows the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Because patients were only queried as aggregates and no protected health information was available for queries, no IRB approval was required for the use of this database or the completion of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kostev, K., Kalder, M. 20-year risk of breast cancer recurrence. Breast Cancer Res Treat 168, 765–766 (2018). https://doi.org/10.1007/s10549-017-4636-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4636-3

Search

Navigation